World Health Organization Sounds Concern Over Critical Lack of Weight-Loss Jabs

Under a tenth of people that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the global health agency as it releases its initial advice on the drugs.

Given more than one billion individuals worldwide currently obese, it is calling for broader and more equitable access to these injectable treatments.

According to forecasts, more than two billion will be obese by 2030 without intervention.

"Our new guidelines acknowledges that obesity is a long-term condition that can be treated with holistic and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are major hurdles to universal access to the injections that can aid individuals in losing significant body mass, says the body.

Skinny Jab Scarcity

Despite the current best projected outlook, the supply of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of those who need them, according to the WHO.

The recommendation encourages nations and manufacturers to expand access, by approaches including patent sharing.

Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in multiple nations in 2026.

How Weight-Loss Injections Function

The injections imitate a biological compound to slow digestion, curb appetite and increase the sense of being full so users reduce food intake.

Patients commonly begin shedding pounds after several weeks of starting on the weekly injections.

Studies suggests people may see weight return within a year of stopping the medication, because their normal hunger return.

Being overweight or obese elevates your risk for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.